Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (31-40 of 196) with videos related to

Pageof 20
Sort By:
The Annals of Thoracic Surgery|May 1, 1992
Hemostatic abnormalities in total artificial heart patients as detected by specific blood markersJ M Walenga, D Hoppensteadt, J Fareed, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspectiveD E Wallis, B E Lewis, J M Walenga
Seminars in Thrombosis and Hemostasis|April 1, 1991
Report on a discussion forum: "Medical and surgical application of recombinant hirudin"J M Walenga, F Markwardt, K Breddin, et al.
Expert Opinion on Investigational Drugs|July 5, 2005
Synthetic and recombinant antithrombin drugsB Kaiser, D Callas, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndromeB E Lewis, J M Walenga, D E Wallis
Seminars in Thrombosis and Hemostasis|October 1, 1989
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparinD Hoppensteadt, A Racanelli, J M Walenga, et al.
Thrombosis Research|June 1, 1995
Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis modelK Fu, R Izquierdo, J M Walenga, et al.
Thrombosis Research|May 1, 1996
Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole bloodB Kaiser, M Koza, J M Walenga, et al.
Drugs of Today (Barcelona, Spain : 1998)|July 9, 2003
Bleeding complications with glycoprotein IIb/IIIa inhibitorsO Iqbal, J M Walenga, B E Lewis, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1983
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methodsL G Svendsen, J Fareed, J M Walenga, et al.
Pageof 20

Showing results (31-40 of 196) with videos related to

Sort By:
Pageof 20
The Annals of Thoracic Surgery|May 1, 1992
Hemostatic abnormalities in total artificial heart patients as detected by specific blood markersJ M Walenga, D Hoppensteadt, J Fareed, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspectiveD E Wallis, B E Lewis, J M Walenga
Seminars in Thrombosis and Hemostasis|April 1, 1991
Report on a discussion forum: "Medical and surgical application of recombinant hirudin"J M Walenga, F Markwardt, K Breddin, et al.
Expert Opinion on Investigational Drugs|July 5, 2005
Synthetic and recombinant antithrombin drugsB Kaiser, D Callas, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndromeB E Lewis, J M Walenga, D E Wallis
Seminars in Thrombosis and Hemostasis|October 1, 1989
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparinD Hoppensteadt, A Racanelli, J M Walenga, et al.
Thrombosis Research|June 1, 1995
Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis modelK Fu, R Izquierdo, J M Walenga, et al.
Thrombosis Research|May 1, 1996
Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole bloodB Kaiser, M Koza, J M Walenga, et al.
Drugs of Today (Barcelona, Spain : 1998)|July 9, 2003
Bleeding complications with glycoprotein IIb/IIIa inhibitorsO Iqbal, J M Walenga, B E Lewis, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1983
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methodsL G Svendsen, J Fareed, J M Walenga, et al.
Pageof 20